Smart Skin's Quantifeel Technology is delivering cost savings and a greater degree of safe medicine handling for Pharmaceutical manufacturers.
When delivering life-saving medicines from the manufacturing plant to the patient, it is of great importance that the medicines arrive without damage that might harm the patient. In the case of medicines filled into glass vials, it is paramount that manufacturers identify weak points and improper set points in the packaging line to prevent the occurrence of defects which may lead to a recall.
"The administration of a glass particulate, if present in an intravenous drug, poses a potential safety risk to patients such as a thromboembolism or a life-threatening pulmonary emboli. Other events such as phlebitis, mechanical block of the capillaries or arterioles, activation of platelets, or subsequent generation of microthrombi are also possible. Patients with a preexisting condition of trauma or other medical condition that adversely affects the microvascular blood supply are at an increased risk. Administration of a glass particulate can also lead to formation of granulomas, which represent a protective local inflammatory response to the foreign material."
- FDA, Recall - Presence of Particulate Matter, Cubicin, 2014
Should defects in the glass (such as scratches and bruises) be identified the ability to immediately locate, isolate and take corrective action in the fastest manner possible, is of the utmost importance. Quantifiable data is needed to prove that changes to the packaging line have corrected the problem and improved safe handling of the product.